CN105663966A - Composition used for slimming and reducing lipid - Google Patents
Composition used for slimming and reducing lipid Download PDFInfo
- Publication number
- CN105663966A CN105663966A CN201610128292.6A CN201610128292A CN105663966A CN 105663966 A CN105663966 A CN 105663966A CN 201610128292 A CN201610128292 A CN 201610128292A CN 105663966 A CN105663966 A CN 105663966A
- Authority
- CN
- China
- Prior art keywords
- reducing
- weight
- compositions
- pulverize
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 150000002632 lipids Chemical class 0.000 title abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 28
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims abstract description 21
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 claims abstract description 21
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 229940018333 calcium pyruvate Drugs 0.000 claims abstract description 11
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 235000015091 medicinal tea Nutrition 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 29
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 22
- 239000012567 medical material Substances 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 19
- -1 filters Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 11
- 229930182830 galactose Natural products 0.000 claims description 11
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 11
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 abstract description 15
- 235000020824 obesity Nutrition 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 abstract 2
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 244000062241 Kaempferia galanga Species 0.000 abstract 1
- 235000013421 Kaempferia galanga Nutrition 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 240000003915 Lophatherum gracile Species 0.000 abstract 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 abstract 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 241000700159 Rattus Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 9
- 206010033307 Overweight Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000004260 weight control Methods 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- IWFHOSULCAJGRM-UAKXSSHOSA-N 5-bromouridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(Br)=C1 IWFHOSULCAJGRM-UAKXSSHOSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition used for slimming and reducing lipid. The invention discloses a new composition formed by lily, galangal, 1-deoxynojirimycin, nuciferine, pagodatree flower buds, kudzu vine root, poria cocos, kelp, lophatherum gracile and functional oligosaccharide, calcium pyruvate and/or L-carnitine also can be added, series preparations such as capsules, tablets, powder, granules, oral liquid and medicinal tea can be prepared according to practical requirements, and a more advanced dosage form can be prepared to be used by a consumer by virtue of a newer technology. The composition can be applied to compositions of common food, functional food, health care products and medicines and can be used for slimming and lipid-reducing health care of obese people and prevention and treatment of obesity.
Description
Technical field
The present invention relates to a kind of compositions for weight-reducing, blood fat reducing, the compositions of the present invention can be used for the compositions of bread and cheese, functional food, health product and medicine and directly uses or refine out use after corresponding active component through modern means of science and technology, make applicable preparation, be widely used in the Crowded health protections such as the metabolic syndrome such as obese people, hyperlipidemia, treatment category.
Background technology
Obesity is the healthy topic of what a Sheng of a specified duration did not wane, associates the population in the whole world about 13%. According to the up-to-date report display of one, obesity community of the world (WOF), unless government takes further action, ending global obesity rates in 2025 will rise 4% again.
Overweight and fat can cause a series of health problem, including heart disease, apoplexy, type-II diabetes and cancer etc. Since nineteen eighty, the prevalence that the whole world is fat has increased and has exceeded one times. Data rise violently largely to be increased owing to the amount of food rich in fat, Sugared beverages, and the motionless working environment of sitting, urban population increase etc.
In order to slow down degradating trend, containment potential risk, World Health Organization (WHO) (WHO) releases a Universal Mobile plan 2013--the year two thousand twenty prevention and control noninfectious problem. Plan is intended to call world community government to participate in estimating compared to 2010, overweight and fat ratio in 2025.
In report also prediction cut-off 2025, the whole world nearly 2,700,000,000 adults can overweight or fat (BMI 25), add more than 700,000,000 than 2014 annual datas. And this is wherein, the contribution surely belonging to the U.S. is maximum, and estimating more than 190,000 adults will be overweight or fat at coming 10 years.
Obesity community of world chairman professor WalmirCoutinho points out, problem of obesity has spread to almost each country of the whole world. Government's this trend already known can not be developed as one pleases, and they have agreed to solve problem of obesity and reduce fat prevalence in 2025 to level in 2010. But, for realizing this target, take action in time now. Doctor Lobstein points out, national governments need to release fat, the overweight strategy of reply, including formulating the strict regulations forbidding selling unhealthy food, to promote health diet, allows health food is less expensive, be more easy to acquisition.
World health community also requires that overweight or population of being obese are provided by Ministry of Public Health and helps further, for instance the rationally popularization of fat-reducing, Weight management project.
Obesity community of the world (WOF) official website is announced, on October 11st, 2015, as the first world obesity commemoration day, pays close attention to raising common people's consciousness, the measure of common discussion obesity controlling by holding " world's obesity day " movable attraction media.
Past antiobesity agents is divided into two kinds: prevent the medicine (lipase inhibitor) of some fat absorption and the medicine (appetite suppressant) of appetite-suppressing, as Aomei department he (lipase inhibitor) can prevent the enzyme in digestive tract the absorbent little molecule of steatolysis behaviour body in diet. The absorption of fat decreases about 30%, because indigested fat is not absorbed, body weight control can be had clear and definite effect by the energy intake of minimizing. Phentermine (appetite suppressant) is by changing 5-hydroxy tryptamine level in the brain, and then reduces appetite. It can cause excitement, and blood pressure raises, and increased heart rate, thus adding total metabolism ratio. Also have sibutramine, BUP, diazoxide, amfepramone etc. These medicines are respectively provided with side effect, and side effect relates to the heart valve that aortic valve leaks and mitral valve leaks and damages, and other more serious side effect includes short of breath, dizziness and blurred vision and death etc. Following obesity medicine: hungry palliative, down and other antipsychotic drug, hormone and leptin molecule. Awakening again despite antagonism antiobesity agents research market, it is contemplated that the solution of blockbuster formula medicine also will be difficult to, and this is mainly due at past facing challenges, namely again making doctor and patient recognize the needs of therapeutic agent safety. In view of the market challenges that these are serious, it is contemplated that drugmaker is that in vigilant side effect and the millions of worlds patient service not knowing Drug therapy benefit, by having any problem, heavy road to be walked in they attempts. But, the gate of 1,000,000,000 Yankee dollar markets not also being found knocked surely open by a kind of therapeutic agent one that can provide safely and shoulder obesity to cure.
So, comply with curative effect demand and the demand for security of obese patient's fat-reducing, diet products are developed from plant amedica, can be a long-term trend, so the research of this product has compliance requirements and natural safe meaning, have employed simultaneously " integration of edible and medicinal herbs " medical material of national regulation and defend planning commission specify can as the raw material of new resources raw material, comply with lose weight demand, there is clear and definite innovative significance and social benefit.
Summary of the invention
Goal of the invention: it is an object of the invention to provide a kind of safely and effectively, with the medical material of integration of edible and medicinal herbs and new raw-food material be primary raw material, cheap, the acceptable a kind of compositions for obese patients of people.
Technical scheme is as follows:
A kind of compositions for weight-reducing, blood fat reducing, its active component is extracted by following bulk drugs and is prepared from: Bulbus Lilii 1~5 part, Rhizoma Alpiniae Officinarum 1~5 part, the Flos Sophorae Immaturus 1~10 part, Radix Puerariae 1~10 part, 1~10 part of Poria, Thallus Laminariae (Thallus Eckloniae) 1~10 part, Herba Lophatheri 1~10 part, functional oligose 1~5 part, 1-DNJ 5~20 parts, nuciferine 5~20 parts.
The described compositions for weight-reducing, blood fat reducing, functional oligose is one or several in stachyose, Raffinose, oligofructose, oligomeric xylose, oligomeric galactose, soybean oligo saccharide, dextrinosan.
The described compositions for weight-reducing, blood fat reducing, each 1~5 part possibly together with calcium pyruvate and/or L-carnitine.
The described compositions for weight-reducing, blood fat reducing, preparation method comprises the steps:
(1) Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri are taken, boiling 1~3 time, 4~8 times of amount of water respectively medical material weight, each 1~3 hour, united extraction liquid, filters, and filtrate concentrates, dry, pulverize, obtain extract one.
(2) take Folium Mori or Folium Nelumbinis, be ground into coarse powder, add 55%~95% alcohol heating reflux extract 1~3 time, 4~8 times of alcohol adding amount respectively medical material weight, each 1~3 hour, united extraction liquid, filtering, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then silica gel H purification is adopted, gained purified, through 95% alcohol crystal, obtains 1-DNJ and nuciferine respectively, dry, pulverize, obtain extract two and three.
(3) said extracted thing one, two and three is merged, add stachyose, pulverize, mix, make capsule, tablet, powder, granule, oral liquid, medicinal tea.
The described compositions for weight-reducing, blood fat reducing, preparation method comprises the steps:
(1) Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri are taken, boiling 1~3 time, 4~8 times of amount of water respectively medical material weight, each 1~3 hour, united extraction liquid, filters, and filtrate concentrates, dry, pulverize, obtain extract one.
(2) take Folium Mori or Folium Nelumbinis, be ground into coarse powder, add 55%~95% alcohol heating reflux extract 1~3 time, 4~8 times of alcohol adding amount respectively medical material weight, each 1~3 hour, united extraction liquid, filtering, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then silica gel H purification is adopted, gained purified, through 95% alcohol crystal, obtains 1-DNJ and nuciferine respectively, dry, pulverize, obtain extract two and three.
(3) said extracted thing one, two and three is merged, add functional oligose, calcium pyruvate and/or L-carnitine, pulverize, mix, make capsule, tablet, powder, granule, oral liquid, medicinal tea.
The described compositions for weight-reducing, blood fat reducing is used for the application in weight-reducing, fat-reducing medicament and health product in preparation.
Beneficial effect: the new raw-food material for weight-reducing, the new compositions medical material from " integration of edible and medicinal herbs " of blood fat reducing and state approval of the present invention, mainly it is made up of Bulbus Lilii extract, Rhizoma Alpiniae Officinarum extract, Huai Goat, Radix Puerariae extract, Poria extract, Thallus Laminariae (Thallus Eckloniae) extract, Herba Lophatheri extract, functional oligose, 1-DNJ, nuciferine, calcium pyruvate and (or) L-carnitine can also be added on this basis, make the different preparation being suitable for and use. Oligosaccharide used is new raw-food material or the food additive of state approval, such as stachyose, Raffinose, oligofructose, oligomeric xylose, oligomeric galactose, soybean oligo saccharide, dextrinosan etc.
The weight-reducing of the present invention, blood fat reducing new compositions from the effective integration of edible and medicinal herbs Chinese crude drug of pure natural and new raw-food material, belong to the effect playing fat-reducing, blood fat reducing of too many levels stage construction Mutiple Targets, the effect for the treatment of both the principal and secondary aspects of a disease is played by this compositions, life-time service complies fully with economics requirement, and the effect that life-time service overweight people brings is worth and is far longer than its monetary cost paid.
Above component is made according to actual needs the preparation series such as capsule, tablet, powder, granule, oral liquid, medicinal tea, more advanced dosage form can also be made for consumer by the technology updated, reach quality controllable, in order to be effective, use safety, it is easy to produce, it is simple to transport, it is simple to the purposes such as storage.
Of the present invention for weight-reducing, the new compositions of blood fat reducing, have employed the thinking for the treatment of both the principal and secondary aspects of a disease, it is repeated for modern society's crowd characteristic prescription, in modern society, all ages and classes stratum focuses on maintenance and nourishes all very much, because health knowledge is relatively deficient, say what others say, carelessly use the diet of tonic and high heat, cause that endotrophic is superfluous, the excessive transporting of taste and tired, cause weakness of the spleen and stomach, injure the day after tomorrow of people, internal phlegm-damp can not be excreted, injure yang-energy simultaneously, plus the random life of youngster and excessive diet raw food goods, cause general YIN-excess body constitution, YIN-excess then negative and positive tool void, so a lot of weight reduction products can not play good effect now, only open YIN-excess and function of spleen and stomach regulating function, add the product of suitable lowering blood-fat and reducing weight, could really play the effect of health slimming, so this product is just built upon prescription on above innovation theory basis: Bulbus Lilii yin nourishing is calmed the nerves, regulate rule of life, nourishing lung and kidney, make raw sun in the moon, Rhizoma Alpiniae Officinarum warming stomach for dispelling cold, melts the YIN-excess of cold syndrome of the stomach, and the transportation capabilities making taste are normal, negative and positive symbiosis accomplished by above two taste medicines, and spleen invigorating of dispeling cold is monarch drug. Poria spleen invigorating, promoting diuresis to eliminate damp pathogen, mind calming, Folium Mori ascending the clear and descending the turbid, Folium Nelumbinis dampness removing, spleen invigorating, yang invigorating, Radix Puerariae yang invigorating, four Chinese medicine shares the effect playing spleen invigorating, dampness removing, yang invigorating, the turbid descending, adds the function of monarch drug, is ministerial drug altogether. Flos Sophorae Immaturus liver heat removing removing heat from blood, Thallus Laminariae (Thallus Eckloniae) hard masses softening and resolving, expectorant, diuretic, Herba Lophatheri body gently oozes to be let out, and YIN-excess, expectorant fertilizer that three taste medicines melt the medicine of the monarch and his subjects jointly are got rid of external, play assistant so as to the effect of medicine, then coordinate the effect of functional oligose regulating intestinal canal flora so that human body returns health status.
The medicine of above monarch, has ascending the clear and descending the turbid, yang invigorating invigorating spleen to remove dampness, the effect of eliminating phlegm of invigorating blood circulation, then coordinates calcium pyruvate and (or) L-carnitine, jointly plays weight-reducing, blood fat reducing, the health care of blood sugar lowering, prevention and therapeutical effect.
Detailed description of the invention
Below the technical scheme in the embodiment of the present invention is clearly and completely described, it is clear that described embodiment is only a part of embodiment of the present invention, rather than whole embodiments. Based on embodiments of the invention, all other embodiments that those of ordinary skill in the art obtain under not making creative work premise, broadly fall into protection scope of the present invention.
Embodiment 1: take Folium Mori 10kg, be ground into coarse powder, adds 95% alcohol heating reflux and extracts 1 time, 8 times of alcohol adding amount respectively medical material weight, each 3 hours, united extraction liquid, filter, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then adopts silica gel purification, gained purified is through 95% alcohol crystal, obtain 1-DNJ, dry, pulverize.
Embodiment 2: take Folium Nelumbinis 10kg, be ground into coarse powder, adds 95% alcohol heating reflux and extracts 1 time, 8 times of alcohol adding amount respectively medical material weight, each 3 hours, united extraction liquid, filter, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then adopts silica gel purification, gained purified is through 95% alcohol crystal, obtain nuciferine, dry, pulverize.
Embodiment 3: take Folium Mori 10kg, be ground into coarse powder, adds 55% alcohol heating reflux and extracts 3 times, 4 times of alcohol adding amount respectively medical material weight, each 1 hour, united extraction liquid, filter, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then adopts silica gel H purification, gained purified is through 95% alcohol crystal, obtain 1-DNJ, dry, pulverize.
Embodiment 4: take Folium Nelumbinis 10kg, be ground into coarse powder, adds 55% alcohol heating reflux and extracts 3 times, 4 times of alcohol adding amount respectively medical material weight, each 1 hour, united extraction liquid, filter, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then adopts silica gel H purification, gained purified is through 95% alcohol crystal, obtain nuciferine, dry, pulverize.
Embodiment 5. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 5 parts of Herba Lophatheri, 1 part of stachyose, 1-DNJ 20 parts, nuciferine 5 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 1 time, 8 times of amount of water respectively medical material weight, each 3 hours, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 1 and 2 respectively obtains, merge, add stachyose, pulverize, mix, add conventional excipient, prepare into tablet.
Embodiment 6. prescription: Bulbus Lilii 1 part, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 10 parts of Herba Lophatheri, 1 part of stachyose, 1-DNJ 5 parts, nuciferine 20 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 2 times, 6 times of amount of water respectively medical material weight, each 2 hours, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 3 and 4 respectively obtains, merge, add stachyose, pulverize, mix, add conventional excipient, prepare into granule.
Embodiment 7. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 1 part, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 1 part of Herba Lophatheri, 1 part of stachyose, 1-DNJ 20 parts, nuciferine 5 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 3 times, 4 times of amount of water respectively medical material weight, each 1 hour, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 1 and 2 respectively obtains, merge, add stachyose, pulverize, mix, add conventional excipient, prepare into oral liquid.
Embodiment 8. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 2 parts of Herba Lophatheri, oligomeric galactose 5 parts, calcium pyruvate 1 part, 1-DNJ 20 parts, nuciferine 5 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 1 time, 8 times of amount of water respectively medical material weight, each 3 hours, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 1 and 2 respectively obtains, merge, add oligomeric galactose, calcium pyruvate, pulverizes, mixes, prepare into capsule.
Embodiment 9. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 2 parts of Herba Lophatheri; Oligomeric galactose 5 parts, calcium pyruvate 1 part, L-carnitine 5 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 2 times, 6 times of amount of water respectively medical material weight, each 2 hours, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 3 and 4 respectively obtains, merge, add oligomeric galactose, calcium pyruvate, L-carnitine, pulverize, mix, prepare into capsule.
Embodiment 10. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 2 parts of Herba Lophatheri, oligomeric galactose 5 parts, L-carnitine 1 part.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 3 times, 4 times of amount of water respectively medical material weight, each 1 hour, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 3 and 4 respectively obtains, merge, add oligomeric galactose, L-carnitine, pulverizes, mixes, prepare into capsule.
Embodiment 11. prescription: Bulbus Lilii 5 parts, Rhizoma Alpiniae Officinarum 5 parts, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), each 2 parts of Herba Lophatheri, oligomeric galactose 5 parts, L-carnitine 5 parts.
Take Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri, boiling 3 times, 4 times of amount of water respectively medical material weight, each 1 hour, united extraction liquid, filter, filtrate concentrates, and dry, pulverize, obtain extract, add 1-DNJ and nuciferine that above-described embodiment 3 and 4 respectively obtains, merge, add oligomeric galactose, L-carnitine, pulverizes, mixes, prepare into capsule.
Embodiment 12. present invention loses weight, the pharmacological action of blood fat reducing
Experimentation: take sample prepared by above-described embodiment 5 method as test medication, take SD rat 50, it is divided into 5 groups, often group 10, respectively blank group, high fat group, medication group (high, medium and low), high, medium and low dose is 16g/kg, 8g/kg, 4g/kg, amount is grouped after terminating respectively, control rats continues to give normal feedstuff and freely ingests every day, what other rats in test groups gave high lipid food in sky starts simultaneously at administration, the distilled water of high fat group rat oral gavage equivalent, the continuous gavage of each group 30 days.
When experiment terminates, rat puts to death front fasting 12 hours, do not cut off the water supply, measuring its body weight, then disconnected neck puts to death rat, takes blood, after room temperature stands, low-temperature centrifugation (3000r/min) lOmin, taking serum, to be placed in-20 DEG C of refrigerators to be checked, adopts test kit enzymic colorimetric to measure serum total cholesterol (TC), total TG (TG), HDL-C (HDL-C) after blood treatment.
Research shows, rat body weight is had obvious intervention effect by this compositions, hence it is evident that lose weight; Rat TC, TG there are is obvious intervention effect, HDL-C is had rising effect. Result is in Table 1-2.
The table 1 impact on rat body weight
Note: test group compares * P < 0.05, * * P < 0.01 with blank group; Test group compares #P < 0.05, ##P < 0.01 with model group.
The table 2 impact on rat fat
Note: test group compares * P < 0.05, * * P < 0.01 with high fat group.
Combinations of the above thing has effect of weight-reducing, blood fat reducing, so body weight control is had effect by this compositions, it is possible to reduce the generation of obesity.
Embodiment 13. present invention loses weight, the pharmacological action of blood fat reducing
Experimentation: take sample prepared by above-described embodiment 9 method as test medication, take SD rat 50, it is divided into 5 groups, often group 10, respectively blank group, high fat group, medication group (high, medium and low), high, medium and low dose is 16g/kg, 8g/kg, 4g/kg, after packet terminates, control rats continues to give normal feedstuff and freely ingests every day, what other rats in test groups gave high lipid food in sky starts simultaneously at administration, the distilled water of high fat group rat oral gavage equivalent, the continuous gavage of each group 30 days.
When experiment terminates, rat puts to death front fasting 12 hours, do not cut off the water supply, measuring its body weight, then disconnected neck puts to death rat, takes blood, after room temperature stands, low-temperature centrifugation (3000r/min) lOmin, taking serum, to be placed in-20 DEG C of refrigerators to be checked, adopts test kit enzymic colorimetric to measure serum total cholesterol (TC), total TG (TG), HDL-C (HDL-C) after blood treatment.
Research shows, rat body weight is had obvious intervention effect by this compositions, hence it is evident that lose weight; Rat TC, TG there are is obvious intervention effect, HDL-C is had rising effect. Result is in Table 3-4.
The table 3 impact on rat body weight
Note: test group compares * P < 0.05, * * P < 0.01 with blank group; Test group compares #P < 0.05, ##P < 0.01 with model group.
The table 4 impact on rat fat
Note: test group compares * P < 0.05, * * P < 0.01 with high fat group.
Combinations of the above thing has effect of weight-reducing, blood fat reducing, so body weight control is had effect by this compositions, it is possible to reduce the generation of obesity.
This compositions and similar condition ratio, raw material chemicals of the present invention is of fine quality to be easy to get, determined curative effect, have simplicity, efficiently, safety, and less costly, simple to operate, replicability strong, application prospect advantage widely.
The above; being only the present invention preferably detailed description of the invention, but protection scope of the present invention is not limited thereto, any those familiar with the art is in the technical scope of present disclosure; the change that can readily occur in or replacement, all should be encompassed within protection scope of the present invention. Therefore, protection scope of the present invention should be as the criterion with the protection domain of claims.
Claims (6)
1. the compositions for weight-reducing, blood fat reducing, it is characterised in that: its active component is extracted by following bulk drugs and is prepared from: Bulbus Lilii 1~5 part, Rhizoma Alpiniae Officinarum 1~5 part, the Flos Sophorae Immaturus 1~10 part, Radix Puerariae 1~10 part, 1~10 part of Poria, Thallus Laminariae (Thallus Eckloniae) 1~10 part, Herba Lophatheri 1~10 part, functional oligose 1~5 part, 1-DNJ 5~20 parts, nuciferine 5~20 parts.
2. according to claim 1 for the compositions of weight-reducing, blood fat reducing, it is characterised in that: functional oligose is one or several in stachyose, Raffinose, oligofructose, oligomeric xylose, oligomeric galactose, soybean oligo saccharide, dextrinosan.
3. according to claim 1 for the compositions of weight-reducing, blood fat reducing, it is characterised in that: each 1~5 part possibly together with calcium pyruvate and/or L-carnitine.
4. according to claim 1 for the compositions of weight-reducing, blood fat reducing, it is characterised in that: preparation method comprises the steps:
(1) Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri are taken, boiling 1~3 time, 4~8 times of amount of water respectively medical material weight, each 1~3 hour, united extraction liquid, filters, and filtrate concentrates, dry, pulverize, obtain extract one.
(2) take Folium Mori or Folium Nelumbinis, be ground into coarse powder, add 55%~95% alcohol heating reflux extract 1~3 time, 4~8 times of alcohol adding amount respectively medical material weight, each 1~3 hour, united extraction liquid, filtering, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then silica gel H purification is adopted, gained purified, through 95% alcohol crystal, obtains 1-DNJ and nuciferine respectively, dry, pulverize, obtain extract two and three.
(3) said extracted thing one, two and three is merged, add functional oligose, pulverize, mix, make capsule, tablet, powder, granule, oral liquid, medicinal tea.
5. according to claim 3 for the compositions of weight-reducing, blood fat reducing, it is characterised in that: preparation method comprises the steps:
(1) Bulbus Lilii, Rhizoma Alpiniae Officinarum, the Flos Sophorae Immaturus, Radix Puerariae, Poria, Thallus Laminariae (Thallus Eckloniae), Herba Lophatheri are taken, boiling 1~3 time, 4~8 times of amount of water respectively medical material weight, each 1~3 hour, united extraction liquid, filters, and filtrate concentrates, dry, pulverize, obtain extract one.
(2) take Folium Mori or Folium Nelumbinis, be ground into coarse powder, add 55%~95% alcohol heating reflux extract 1~3 time, 4~8 times of alcohol adding amount respectively medical material weight, each 1~3 hour, united extraction liquid, filtering, filtrate is recycled to without alcohol taste, and recovered liquid passes through cation exchange resin purification, then silica gel H purification is adopted, gained purified, through 95% alcohol crystal, obtains 1-DNJ and nuciferine respectively, dry, pulverize, obtain extract two and three.
(3) said extracted thing one, two and three is merged, add stachyose, calcium pyruvate and/or L-carnitine, pulverize, mix, make capsule, tablet, powder, granule, oral liquid, medicinal tea.
6. the compositions for weight-reducing, blood fat reducing according to claim 1 is used for the application in weight-reducing, fat-reducing medicament and health product in preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610128292.6A CN105663966A (en) | 2016-03-07 | 2016-03-07 | Composition used for slimming and reducing lipid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610128292.6A CN105663966A (en) | 2016-03-07 | 2016-03-07 | Composition used for slimming and reducing lipid |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105663966A true CN105663966A (en) | 2016-06-15 |
Family
ID=56307012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610128292.6A Withdrawn CN105663966A (en) | 2016-03-07 | 2016-03-07 | Composition used for slimming and reducing lipid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663966A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109770145A (en) * | 2019-01-03 | 2019-05-21 | 西安源森生物科技有限公司 | A kind of auxiliary improves the solid beverage and preparation method thereof of disorders of lipid metabolism |
CN112043683A (en) * | 2020-08-06 | 2020-12-08 | 中国计量大学 | Preparation method of lipid-lowering/weight-reducing compound hydrogel |
CN114521601A (en) * | 2021-12-30 | 2022-05-24 | 海南三风友制药有限公司 | Beverage composition for losing weight and reducing fat and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623495A (en) * | 2009-08-04 | 2010-01-13 | 天圣制药集团股份有限公司 | Chinese medicine composition for regulating blood fat and decreasing blood sugar and preparation method thereof |
CN103055057A (en) * | 2012-08-31 | 2013-04-24 | 中国科学院生物物理研究所 | Plant weight-losing and fat-reducing composite compatible to L-carnitine |
-
2016
- 2016-03-07 CN CN201610128292.6A patent/CN105663966A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623495A (en) * | 2009-08-04 | 2010-01-13 | 天圣制药集团股份有限公司 | Chinese medicine composition for regulating blood fat and decreasing blood sugar and preparation method thereof |
CN103055057A (en) * | 2012-08-31 | 2013-04-24 | 中国科学院生物物理研究所 | Plant weight-losing and fat-reducing composite compatible to L-carnitine |
Non-Patent Citations (1)
Title |
---|
梁明等: "1-脱氧野尻霉素的研究进展", 《安徽农业科学》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109770145A (en) * | 2019-01-03 | 2019-05-21 | 西安源森生物科技有限公司 | A kind of auxiliary improves the solid beverage and preparation method thereof of disorders of lipid metabolism |
CN112043683A (en) * | 2020-08-06 | 2020-12-08 | 中国计量大学 | Preparation method of lipid-lowering/weight-reducing compound hydrogel |
CN114521601A (en) * | 2021-12-30 | 2022-05-24 | 海南三风友制药有限公司 | Beverage composition for losing weight and reducing fat and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058817B (en) | Tibetan medicinal preparation for treating liver diseases | |
CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
WO2016127463A1 (en) | Medicine for protecting the liver, removing toxins, reducing blood lipids and reducing blood sugar and use thereof | |
CN104740541A (en) | Health-care traditional Chinese medicine powder for protecting liver, detoxifying and recovering liver functions | |
CN102550738B (en) | Health-care tea capable of preventing radiation and improving immunity and preparation method thereof | |
CN105663966A (en) | Composition used for slimming and reducing lipid | |
CN104940645A (en) | Dendrobium officinale traditional Chinese medicine composition with functions of maintaining beauty and keeping young and preparation of dendrobium officinale traditional Chinese medicine composition | |
CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
CN105535777A (en) | Composition for weight reduction and lipid decreasing | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN110898201B (en) | A topical Chinese medicinal composition for removing food stagnation in children, and its preparation method | |
CN104922299A (en) | Traditional Chinese medicine healthcare oral liquid used for preventing and treating diabetic retinopathy | |
CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
CN103520302B (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
CN103156956B (en) | Blood replenishing oral liquid and preparation method thereof | |
CN1286508C (en) | Compound health tea | |
CN105707880A (en) | Health-care food and preparation method thereof | |
CN104474108A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and preparation method of traditional Chinese medicine preparation | |
CN104524215B (en) | Treat capsule of stomach trouble and preparation method thereof | |
CN102132870A (en) | Diet health-care product and preparation method thereof | |
CN104857363A (en) | Combined Chinese herbal preparation for reducing blood fat and preparation method thereof | |
CN104800600A (en) | Medicine for treating hypertension | |
CN102846844A (en) | Composition for constitution with Yin-deficiency, as well as preparation method and application thereof | |
CN109078089A (en) | A kind of anti-aging, the Chinese medicine composition and its preparation for preventing and treating osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180131 Address after: 321000 7 building, No. 1-1 scientific research building, No. 589, Longtan Road, Wucheng District, Jinhua, Zhejiang Applicant after: Jinhua Huasai Pharmaceutical Research Institute Co., Ltd. Address before: 210019 50 Jin An street, Jianye District, Jiangsu, Nanjing Province, 9-218 Applicant before: Shi Zhenping |
|
TA01 | Transfer of patent application right | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160615 |
|
WW01 | Invention patent application withdrawn after publication |